Yazar "Adaş, Gökhan" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial
    (Sage Journals, 2021) Adaş, Gökhan; Çukurova, Zafer; Kart Yaşar, Kadriye; Yılmaz, Rabia; Işıksaçan, Nilgün; Kasapoğlu, P.; Yeşilbağ, Zuhal; Koyuncu Irmak, Duygu; Karaöz, Erdal
    The aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 106 cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFN?, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-?, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients.
  • Küçük Resim Yok
    Öğe
    The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial
    (WILEY, 2021) Adaş, Gökhan; Işıksaçan, Nilgün; Atar, Pınar; Çukurova, Zafer; Yaşar, Kadriye Kart; Yılmaz, Rabia; Yeşilbağ, Zuhal; Koyuncu Irmak, Duygu; Karaöz, Erdal
    [No Abstract Available]
  • Küçük Resim
    Öğe
    Wharton's jelly-derived mesenchymal stem cell transplantation in a patient with hypoxic-ischemic encephalopathy: a pilot study
    (Sage Publications Inc, 2018) Kabataş, Serdar; Civelek, Erdinç; İnci, Çiğdem; Yalçınkaya, Ebru Yılmaz; Günel, Gülşen; Kır, Gülay; Albayrak, Esra; Öztürk, Erek; Adaş, Gökhan; Karaöz, Erdal
    Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have been introduced as a possible therapy in hypoxic-ischemic encephalopathy (HIE). We report a 16-year-old boy who was treated with WJ-MSCs in the course of HIE due to post-cardiopulmonary resuscitation. He received a long period of mechanical ventilation and tracheostomy with spastic quadriparesis. He underwent the intrathecal (1x10(6)/kg in 3 mL), intramuscular (1x10(6)/kg in 20 mL) and intravenous (1x10(6)/kg in 30 mL) administrations of WJ-MSCs for each application route (twice a month for 2 months). After stem cell infusions, progressive improvements were shown in his neurological examination, neuroradiological, and neurophysiological findings. To our best knowledge, this is a pioneer project to clinically study the neural repair effect of WJ-MSCs in a patient with HIE.